Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21338058 | 1.00 | OPRM1 (0.46) | OPRM1OPRD1OPRK1NR1I2KCNH2 | |
| SCHEMBL21023520 | 0.81 | OPRM1 (0.35) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13707246 | 0.79 | OPRM1 (0.49) | OPRM1OPRD1OPRK1 | |
| SCHEMBL21338056 | 0.78 | OPRD1 (0.40) | OPRM1OPRD1OPRK1NR1I2KCNH2 | |
| SCHEMBL13292622 | 0.74 | OPRD1 (0.45) | OPRM1OPRD1OPRK1 | |
| SCHEMBL18056759 | 0.72 | OPRM1 (0.54) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL18104558 | 0.71 | OPRM1 (0.44) | OPRM1OPRD1OPRK1NR1I2KCNH2 | |
| SCHEMBL12305091 | 0.71 | OPRM1 (0.51) | OPRM1OPRD1OPRK1PKMLMNA | |
| SCHEMBL12305078 | 0.71 | OPRM1 (0.51) | OPRM1OPRD1OPRK1PKMLMNA | |
| SCHEMBL15071364 | 0.70 | OPRM1 (0.45) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151309-A1 | COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151309-A1 | COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS | SLC6A1, SLC6A11, SLC6A2 | OPRM1 13/4885OPRD1 22/4885OPRK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.